PT-141 serves as a cutting-edge cyclic melanocortin agonist that demonstrates potential in the treatment of sexual dysfunction. This novel compound acts by enhancing specific receptors within the body, resulting to improved sexual response. Preclinical studies have suggested that PT-141 could effectively address a spectrum of sexual dysfunctions i